This was the stock's second consecutive day of losses.

The stock's fall snapped a two-day winning streak.

Regeneron Pharmaceuticals has declined to submit a new bid for genetic testing company 23andMe exceeding its original winning ...

Anne Wojcicki is taking back reins of 23andMe after outbidding Regeneron. The entrepreneur's proposal offers better ...

Anne Wojcicki is set to regain control of 23andMe after a $305 million bid from a nonprofit she controls topped Regeneron ...

AI data centers need energy, and that’s what’s made the stock price of aptly-named NRG $NRG rise 88% in the past year ...

The S&P 500 added 0.6% on Tuesday, June 10, 2025, as investors awaited developments in the trade negotiations between the U.S ...

U.S. equities were mostly edging higher at midday with the market watching for developments in U.S.-China trade negotiations.

Regeneron Pharmaceuticals just got a haircut from Wall Street, with JPMorgan Chase & Co. lowering its price target from $950 ...

Regeneron stock just slipped on a banana peel, hitting a 52-week low at $493.15 before closing at $496.06. Despite this dip, ...

Regeneron Pharma stock has been in a persistent downtrend for over 280 days. Here's why you should avoid REGN.

Kenvue Inc.'s stock had its worst day in nearly two years on Tuesday, as the maker of Band-Aids, Benadryl and Tylenol said tariffs, persistent inflation and weaker demand for allergy medicine, due to ...